NICE guidance on bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer

The Lancet Oncology

Volumn 14, Issue 8, 2013, Pages 691-692

  Pinilla Dominguez, Pilar ^a   Richardson, Joanna ^a   Robertson, Janet ^a   Adam, Jane ^a  

^a NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; GEMCITABINE; PLATINUM COMPLEX;

ADVANCED CANCER; ARTICLE; BODY SURFACE; BRAIN HEMORRHAGE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; CREATININE CLEARANCE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERTENSION; MULTIPLE CYCLE TREATMENT; NATIONAL HEALTH SERVICE; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; UTERINE TUBE CARCINOMA;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; DRUG COSTS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879784185     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70247-X     Document Type: Article

References (10)

1. Technology appraisal guidance TA285. Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer NICE, May, (accessed May 22, 2013). http://guidance.nice.org.uk/TA285.
2. Single technology appraisal: bevacizumab for the treatment of recurrent advanced ovarian cancer NICE, September, (accessed April 16, 2013). http://www.nice.org.uk/nicemedia/live/13586/62630/62630.pdf.
3. Edwards SJ, Barton S, Thurgar E, et al. Bevacizumab for the treatment of recurrent advanced ovarian cancer: a Single Technology Appraisal report for the BMJ-Technology Assessment Group, (accessed April 16, 2013). http://www.nice.org.uk/nicemedia/live/13586/62620/62620.pdf.
4. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube Cancer. J Clin Oncol 2012, 30:2039-2045.
5. Technology appraisal guidance TA222. Trabectedin for the treatment of relapsed ovarian cancer NICE, April, (accessed April 16, 2013). http://guidance.nice.org.uk/TA222.
6. Monk BJ, Herzog T, Kaye S, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010, 28:3107-3114.
7. Sacco JJ, Botten J, Macbeth F, Bagust A, Clark P The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLoS One 2010, 5:e8933.
8. Avastin: summary of product characteristics European Medicines Agency, November, (accessed April 16, 2013). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf.
9. Ovarian, fallopian tube and primary peritoneal cancer (recurrent, advanced, platinum-sensitive, partially platinum-sensitive)-bevacizumab: appraisal consultation document NICE, January, (accessed April 16, 2013). http://guidance.nice.org.uk/TA/Wave28/1/Consultation/DraftGuidance.
10. Final appraisal determination: bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer NICE, May, (accessed April 16, 2013). http://guidance.nice.org.uk/TA/Wave28/1/FAD.